NEW YORK, March 24, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer' s disease, announced that Dr. Daniel Alkon, M.D., Neurotrope's President and Chief Scientific Officer, is scheduled to present at the Sachs Associates' 2nd Annual Neuroscience Biopartnering and Investment Forum, being held March 27, 2017 at the New York Academy of Sciences in New York City.
Dr. Alkon has been invited to be the keynote speaker at the event. His presentation entitled "A Regenerative Medicine Approach to Neurodegeneration," will take place on Monday, March 27, 2017 at 1:10 pm EDT and lead into the "Advances in Parkinson's Disease and Other Movement Disorders Panel."
Dr. Alkon commented, "I am honored to present a Keynote address at the Sachs Annual Neuroscience Biopartnering & Investment Forum. Neurotrope's pre-clinical and clinical data support the potential of its lead compound, bryostatin-1, to induce the formation of new, mature synaptic networks that could reverse major cognitive deterioration that occurs in Alzheimer's disease (AD). Bryostatin-1 has demonstrated the potential to prevent neuronal death as well as the well-known brain pathologies, amyloid plaques and neurofibrillary tangles. Bryostatin's multiple efficacies, collectively provide an unprecedented opportunity to treat neurodegeneration with a regenerative medicine approach. The Neuroscience Biopartnering & Investment Forum provides a great opportunity to discuss the exciting advances being made in the science of neurodegenerative diseases, promising treatments under development, and bryostatin's position in the arena."
In addition, Neurotrope's Chief Executive Officer Dr. Susanne Wilke PhD, together with Dr. Alkon, will be presenting at 3:00 pm EDT, to discuss the Company's disruptive approach to Alzheimer's disease treatment, current clinical development plan, and upcoming milestones. A live webcast of the presentation will be available online at: https://youtu.be/RVpI0Tj9Kf4.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia.
Neurotrope is conducting a Phase 2 trial of bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin-1 for Alzheimer's dementia and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. The Company does not undertake to update these forward-looking statements.
Please visit www.neurotropebioscience.com for further information.
For additional information, please contact:
Neurotrope BioScience, Inc.
Jeffrey Benison, Director of Corporate Communications
212.334.8709 or 516.286.6099
jbenison@neurotropebioscience.com
SOURCE Neurotrope, Inc.